Harvard Apparatus Regenerative Technology Inc (HRGN)

Harvard Apparatus Regenerative Technology Inc. is a clinical-stage biotechnology company listed on OTC Markets as common stock. The company focuses on regenerative-medicine approaches for disorders affecting the gastrointestinal system and other organs, including conditions linked to cancer, trauma, and birth defects. Its lead candidate is Cellspan Esophageal Implant, which is being developed for severe esophageal disease. The broader pipeline includes organ-regeneration technology aimed at repairing or replacing damaged or diseased organs, as well as product candidates targeting esophageal injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and wound repair in the colon and uterus. In addition to its development activities, the company also sells consumer health products such as dietary supplements. Formerly known as Biostage, Inc., the company adopted its current name in July 2023 and is headquartered in Holliston, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.